Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections

ID
Name
CHT/URC/2023/12
Description
The aim of this retrospective observational study is to evaluate the efficacy of antibiotic therapy with dalbavancin in patients presenting with infection on prosthetic devices. The main questions the study aims to answer are: What is the proportion of patients with early discontinuation of dalbavancin therapy? What are the reasons for early discontinuation of antibiotic treatment? What adverse events do patients report? The study is based on data collected as part of routine care practices. Translated with www.DeepL.com/Translator (free version)
Trial arms
Trial start
2020-01-01
Estimated PCD
2022-12-31
Trial end
2022-12-31
Status
Completed
Treatment
Dalbavancin Injection
Dalbavancin as long-term suppressive therapy.
Size
15
Primary endpoint
efficacy of suppressive Dalbavancin therapy
two-year follow-up after initiation of suppressive therapy with Dalbavancin
Eligibility criteria
Inclusion Criteria: * Patients with inextricable and/or inoperable osteoarticular or vascular prosthetic material. * Patients requiring suppressive antibiotic therapy (\>6 months) with dalbavancin. Exclusion Criteria: * Patients who are protected adult; * Patients who are minors; * Patients having expressed their opposition
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_ONLY', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 15, 'type': 'ACTUAL'}}
Updated at
2023-10-18

1 organization

1 product

1 indication

Organization
Tourcoing Hospital
Product
Dalbavancin
Indication
Prosthesis-related Infections